Nakayama, Atsuko http://orcid.org/0000-0002-5625-8452
Morita, Hiroyuki
Kawahara, Takuya
Itoh, Hiroshi
Komuro, Issei
Funding for this research was provided by:
Restart-up research funding by The University of Tokyo (2018)
Article History
Received: 22 January 2021
Accepted: 14 May 2021
First Online: 26 May 2021
Declarations
:
: H.I. reports grants and personal fees from Shionogi & Co., Ltd during the course of the study, and grants and personal fees from Takeda Pharmaceutical Co. Ltd, Nippon Boehringer Ingelheim Co., Ltd, Daiichi Sankyo Co., Ltd, MSD K.K., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co., Ltd and Taisho Toyama Pharmaceutical Co., Ltd, as well as grants from Sumitomo Dainippon Pharma Co., Ltd, Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd, Teijin Pharma Ltd, Mochida Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K. and personal fees from Nipro Corporation and SBI Pharmaceuticals Co., Ltd outside the submitted work. I.K. reports personal fees from Shionogi & Co., Ltd during the course of the study, grants and personal fees from Takeda Pharmaceutical Co. Ltd, Nippon Boehringer Ingelheim Co., Ltd, Astellas Pharma Inc., Daiichi Sankyo Co., Ltd, and Otsuka Pharmaceutical Co., Ltd and grants from MSD K.K., Shionogi & Co., Ltd, GlaxoSmithKline K.K., Sanofi K.K., Genzyme Japan K.K., Sumitomo Dainippon Pharma Co., Ltd, Mitsubishi Tanabe Pharma Corporation and Bristol‐Myers Squibb Co. outside the submitted work.
: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.